<VariationArchive VariationID="632835" VariationName="NM_000157.4(GBA1):c.595_596del (p.Leu199fs)" VariationType="Deletion" Accession="VCV000632835" Version="34" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="6" DateLastUpdated="2024-07-29" DateCreated="2019-06-03" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="621060" VariationID="632835">
      <GeneList>
        <Gene Symbol="GBA1" FullName="glucosylceramidase beta 1" GeneID="2629" HGNC_ID="HGNC:4177" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>1q22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155234452" stop="155244627" display_start="155234452" display_stop="155244627" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_003315906.1" start="39475" stop="49650" display_start="39475" display_stop="49650" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="155204238" stop="155214652" display_start="155204238" display_stop="155214652" Strand="-" />
          </Location>
          <OMIM>606463</OMIM>
        </Gene>
        <Gene Symbol="LOC106627981" FullName="GBA recombination region" GeneID="106627981" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>1q22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155233639" stop="155240092" display_start="155233639" display_stop="155240092" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_003315906.1" start="38662" stop="45115" display_start="38662" display_stop="45115" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000157.4(GBA1):c.595_596del (p.Leu199fs)</Name>
      <CanonicalSPDI>NC_000001.11:155238298:AG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1q22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155238299" stop="155238300" display_start="155238299" display_stop="155238300" variantLength="2" positionVCF="155238298" referenceAlleleVCF="CAG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="155208090" stop="155208091" display_start="155208090" display_stop="155208091" variantLength="2" positionVCF="155208089" referenceAlleleVCF="CAG" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>L150fs</ProteinChange>
      <ProteinChange>L199fs</ProteinChange>
      <ProteinChange>L112fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.155208090_155208091del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.155208090_155208091del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.155238299_155238300del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.155238299_155238300del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009783.1" sequenceAccession="NG_009783" sequenceVersion="1" change="g.11398_11399del">
            <Expression>NG_009783.1:g.11398_11399del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_042867.1" sequenceAccession="NG_042867" sequenceVersion="1" change="g.4761_4762del">
            <Expression>NG_042867.1:g.4761_4762del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000157.4" sequenceAccession="NM_000157" sequenceVersion="4" change="c.595_596del" MANESelect="true">
            <Expression>NM_000157.4:c.595_596del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000148.2" sequenceAccession="NP_000148" sequenceVersion="2" change="p.Leu199fs">
            <Expression>NP_000148.2:p.Leu199fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005741.3" sequenceAccession="NM_001005741" sequenceVersion="3" change="c.595_596del">
            <Expression>NM_001005741.3:c.595_596del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001005741.1" sequenceAccession="NP_001005741" sequenceVersion="1" change="p.Leu199fs">
            <Expression>NP_001005741.1:p.Leu199fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005742.3" sequenceAccession="NM_001005742" sequenceVersion="3" change="c.595_596del">
            <Expression>NM_001005742.3:c.595_596del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001005742.1" sequenceAccession="NP_001005742" sequenceVersion="1" change="p.Leu199fs">
            <Expression>NP_001005742.1:p.Leu199fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001171811.2" sequenceAccession="NM_001171811" sequenceVersion="2" change="c.334_335del">
            <Expression>NM_001171811.2:c.334_335del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001165282.1" sequenceAccession="NP_001165282" sequenceVersion="1" change="p.Leu112fs">
            <Expression>NP_001165282.1:p.Leu112fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001171812.2" sequenceAccession="NM_001171812" sequenceVersion="2" change="c.448_449del">
            <Expression>NM_001171812.2:c.448_449del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001165283.1" sequenceAccession="NP_001165283" sequenceVersion="1" change="p.Leu150fs">
            <Expression>NP_001165283.1:p.Leu150fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005741.2" sequenceAccession="NM_001005741" sequenceVersion="2" change="c.595_596del">
            <Expression>NM_001005741.2:c.595_596del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000157.4" sequenceAccession="NM_000157" sequenceVersion="4" change="c.595_596delCT" MANESelect="true">
            <Expression>NM_000157.4:c.595_596delCT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="749714463" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="Trans-Omics for Precision Medicine (TOPMed)" />
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00002" Source="Exome Aggregation Consortium (ExAC)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000157.4(GBA1):c.595_596del (p.Leu199fs) AND Gaucher disease" Accession="RCV000780287" Version="3">
        <ClassifiedConditionList TraitSetID="6268">
          <ClassifiedCondition DB="MedGen" ID="C0017205">Gaucher disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-08-16" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.595_596del (p.Leu199fs) AND not provided" Accession="RCV001091725" Version="25">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-03-18" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.595_596del (p.Leu199fs) AND multiple conditions" Accession="RCV002487605" Version="2">
        <ClassifiedConditionList TraitSetID="12838">
          <ClassifiedCondition DB="MedGen" ID="C1842704">Gaucher disease perinatal lethal</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1961835">Gaucher disease type I</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268250">Gaucher disease type II</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268251">Gaucher disease type III</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1856476">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0752347">Lewy body dementia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3160718">Parkinson disease, late-onset</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-03-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.595_596del (p.Leu199fs) AND not specified" Accession="RCV004027316" Version="1">
        <ClassifiedConditionList TraitSetID="9590">
          <ClassifiedCondition DB="MedGen" ID="CN169374">not specified</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-08-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-03-18" NumberOfSubmissions="6" NumberOfSubmitters="6" DateCreated="2019-06-03" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10079102</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10796875</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11783951</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16185900</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16185907</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17059888</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18338393</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9153297</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="12838" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2161" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 3C</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ElementValue>
                <XRef ID="MONDO:0009268" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GAUCHER DISEASE, TYPE IIIC</ElementValue>
                <XRef Type="MIM" ID="231005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0006" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12504" />
                <XRef ID="12504" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="2072" DB="Orphanet" />
              <XRef ID="C1856476" DB="MedGen" />
              <XRef ID="MONDO:0009268" DB="MONDO" />
              <XRef Type="MIM" ID="231005" DB="OMIM" />
            </Trait>
            <Trait ID="3762" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Parkinson's disease</ElementValue>
                <XRef ID="Parkinson+Disease/5603" DB="Genetic Alliance" />
                <XRef ID="49049000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary late onset Parkinson disease</ElementValue>
                <XRef ID="MONDO:0018466" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Susceptibility to Parkinson's Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Parkinson disease, late-onset</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO</ElementValue>
                <XRef Type="Allelic variant" ID="603680.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601517.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="157140.0021" DB="OMIM" />
                <XRef Type="Allelic variant" ID="607047.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0048" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600075.0001" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PARK</ElementValue>
                <XRef Type="MIM" ID="168600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PD</ElementValue>
                <XRef Type="MIM" ID="168600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17684" />
                <XRef ID="17684" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301402</ID>
                <ID Source="BookShelf">NBK1223</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS, 2011">
                <ID Source="PubMed">20482602</ID>
              </Citation>
              <XRef ID="411602" DB="Orphanet" />
              <XRef ID="C3160718" DB="MedGen" />
              <XRef ID="MONDO:0008199" DB="MONDO" />
              <XRef Type="MIM" ID="168600" DB="OMIM" />
            </Trait>
            <Trait ID="1362" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, noncerebral juvenile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid beta-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type I</ElementValue>
                <XRef ID="MONDO:0009265" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher's disease, type 1</ElementValue>
                <XRef ID="Gaucher+Disease+Type+1/3002" DB="Genetic Alliance" />
                <XRef ID="62201009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GBA DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD I</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD1</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2441" />
                <XRef ID="2441" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77259" DB="Orphanet" />
              <XRef ID="C1961835" DB="MedGen" />
              <XRef ID="MONDO:0009265" DB="MONDO" />
              <XRef Type="MIM" ID="230800" DB="OMIM" />
            </Trait>
            <Trait ID="1363" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Acute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+2/3003" DB="Genetic Alliance" />
                <XRef ID="12246008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type II</ElementValue>
                <XRef ID="MONDO:0009266" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, infantile cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, acute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD II</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD2</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2442" />
                <XRef ID="2442" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="77260" DB="Orphanet" />
              <XRef ID="C0268250" DB="MedGen" />
              <XRef ID="MONDO:0009266" DB="MONDO" />
              <XRef Type="MIM" ID="230900" DB="OMIM" />
            </Trait>
            <Trait ID="1364" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Subacute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+3/3004" DB="Genetic Alliance" />
                <XRef ID="5963005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher Disease, Type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type III</ElementValue>
                <XRef ID="MONDO:0009267" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, juvenile and adult, cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, chronic neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, subacute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD III</ElementValue>
                <XRef Type="MIM" ID="231000" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2443" />
                <XRef ID="2443" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77261" DB="Orphanet" />
              <XRef ID="C0268251" DB="MedGen" />
              <XRef ID="MONDO:0009267" DB="MONDO" />
              <XRef Type="MIM" ID="231000" DB="OMIM" />
            </Trait>
            <Trait ID="1913" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease perinatal lethal</ElementValue>
                <XRef ID="MONDO:0011945" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease collodion type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, perinatal-lethal form</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10675" />
                <XRef ID="10675" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="85212" DB="Orphanet" />
              <XRef ID="C1842704" DB="MedGen" />
              <XRef ID="MONDO:0011945" DB="MONDO" />
              <XRef Type="MIM" ID="608013" DB="OMIM" />
            </Trait>
            <Trait ID="1243" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal dominant diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lewy Body Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Lewy body dementia</ElementValue>
                <XRef ID="Lewy+body+dementia/4215" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007488" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">DLB</ElementValue>
                <XRef Type="MIM" ID="127750" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3243" />
                <XRef ID="3243" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg148</URL>
                <CitationText>UK NICE Clinical guideline (CG148), Urinary incontinence in neurological disease: assessment and management, 2023</CitationText>
              </Citation>
              <XRef ID="C0752347" DB="MedGen" />
              <XRef ID="MONDO:0007488" DB="MONDO" />
              <XRef Type="MIM" ID="127750" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9590" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16789" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">AllHighlyPenetrant</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not specified</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not specified' was created for use in ClinVar so that submitters can convey the concept that a variant is benign, likely benign, or of uncertain significance for an unspecified set of disorders.  This usage was introduced in 2014 to replace AllHighlyPenetrant.</Attribute>
              </AttributeSet>
              <XRef ID="CN169374" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6268" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="14198" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease</ElementValue>
                <XRef ID="Gaucher+Disease/3000" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018150" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acute cerebral Gaucher disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebroside lipidosis syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher splenomegaly</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sphingolipidosis 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosylceramidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosyl cerebroside lipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kerasin lipoidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kerasin thesaurismosis</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8233" />
                <XRef ID="8233" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="C0017205" DB="MedGen" />
              <XRef ID="MONDO:0018150" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1794047" SubmissionDate="2019-04-24" DateLastUpdated="2019-06-03" DateCreated="2019-06-03">
        <ClinVarSubmissionID localKey="NM_001005741.2:c.595_596delCT|MedGen:C0017205" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000917430" DateUpdated="2019-06-03" DateCreated="2019-06-03" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-08-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16185907</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17059888</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16185900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18338393</ID>
          </Citation>
          <Comment>Variant summary: GBA c.595_596delCT (p.Leu199AspfsX62) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. A truncation downstream of this position has been classified as pathogenic by our laboratory (e.g., p.Val211fsX20 and p.Tyr343fsX1). The variant allele was found at a frequency of 1.1e-05 in 184208 control chromosomes (gnomAD). c.595_596delCT has been reported in the literature in several individuals affected with Type I Gaucher Disease ((Pomponio_2005, Rozenberg_2006). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.2:c.595_596delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Gaucher disease</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0017205" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5494893</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2877020" SubmissionDate="2020-12-28" DateLastUpdated="2021-01-02" DateCreated="2021-01-02">
        <ClinVarSubmissionID localKey="NM_000157.4:c.595_596delCT|Gaucher disease" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001461745" DateUpdated="2021-01-02" DateCreated="2021-01-02" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000157.4:c.595_596delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Gaucher disease</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8808661</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5428589" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000157.4:c.595_596del|OMIM:127750;168600;230800;230900;231000;231005;608013" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002776207" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000157.4:c.595_596del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="127750" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="168600" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230900" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231005" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="608013" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2720759" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="4327358|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001385934" DateUpdated="2024-02-14" DateCreated="2020-07-16" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16185907</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9153297</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10079102</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10796875</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11783951</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 632835). This premature translational stop signal has been observed in individual(s) with Gaucher disease (PMID: 16185907). This variant is present in population databases (rs749714463, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Leu199Aspfs*62) in the GBA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GBA are known to be pathogenic (PMID: 9153297, 10079102, 10796875, 11783951).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.155208090_155208091del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5390280" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-12-03">
        <ClinVarSubmissionID localKey="a194873|MedGen:CN169374" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002755843" DateUpdated="2024-05-01" DateCreated="2022-12-03" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-08-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16185907</ID>
          </Citation>
          <Comment>The c.595_596delCT pathogenic mutation, located in coding exon 6 of the GBA gene, results from a deletion of two nucleotides at nucleotide positions 595 to 596, causing a translational frameshift with a predicted alternate stop codon (p.L199Dfs*62). This mutation was identified in four individuals with type 1 Gaucher disease in conjunction with p.N409S (Pomponio RJ et al. Mol. Genet. Metab., 2005 Dec;86:466-72). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005742.2:c.595_596delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN169374" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122_ResubmissionBatch1</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2469522" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2020-05-12">
        <ClinVarSubmissionID localKey="101235|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001247923" DateUpdated="2024-07-15" DateCreated="2020-05-12" Type="SCV" Version="23" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="1" alternateAllele="C" referenceAllele="CAG" start="155208089" stop="155208091" variantLength="3" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2021-07</SubmissionName>
          <SubmissionName>2021-10</SubmissionName>
          <SubmissionName>2022-01</SubmissionName>
          <SubmissionName>2022-01-corrected</SubmissionName>
          <SubmissionName>2022-04</SubmissionName>
          <SubmissionName>2022-07</SubmissionName>
          <SubmissionName>2022-08</SubmissionName>
          <SubmissionName>2022-10.3</SubmissionName>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5428589" TraitType="Disease" MappingType="XRef" MappingValue="168600" MappingRef="OMIM">
        <MedGen CUI="C3160718" Name="Parkinson disease, late-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5428589" TraitType="Disease" MappingType="XRef" MappingValue="230900" MappingRef="OMIM">
        <MedGen CUI="C0268250" Name="Gaucher disease type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2720759" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5428589" TraitType="Disease" MappingType="XRef" MappingValue="230800" MappingRef="OMIM">
        <MedGen CUI="C1961835" Name="Gaucher disease type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5428589" TraitType="Disease" MappingType="XRef" MappingValue="608013" MappingRef="OMIM">
        <MedGen CUI="C1842704" Name="Gaucher disease perinatal lethal" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2469522" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5428589" TraitType="Disease" MappingType="XRef" MappingValue="231005" MappingRef="OMIM">
        <MedGen CUI="C1856476" Name="Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2877020" TraitType="Disease" MappingType="Name" MappingValue="Gaucher disease" MappingRef="Preferred">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1794047" TraitType="Disease" MappingType="Name" MappingValue="Gaucher disease" MappingRef="Preferred">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5428589" TraitType="Disease" MappingType="XRef" MappingValue="231000" MappingRef="OMIM">
        <MedGen CUI="C0268251" Name="Gaucher disease type III" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5428589" TraitType="Disease" MappingType="XRef" MappingValue="127750" MappingRef="OMIM">
        <MedGen CUI="C0752347" Name="Lewy body dementia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5390280" TraitType="Disease" MappingType="XRef" MappingValue="CN169374" MappingRef="MedGen">
        <MedGen CUI="CN169374" Name="not specified" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

